B-type natriuretic peptide levels predict event-free survival in patients with implantable cardioverter defibrillators

European Journal of Heart Failure

Volumn 9, Issue 3, 2007, Pages 272-279

  Christ, Michael ^a,c   Sharkova, Julia ^a   Bayrakcioglu, Somer ^a   Herzum, Ileana ^b   Mueller, Christian ^c   Grimm, Wolfram ^a  

^a Klinik fur Innere Medizin   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Brain natriuretic peptide; Cardiac death; Implantable cardioverter defibrillator; Sudden arrhythmic death; Ventricular tachyarrhythmias

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEFIBRILLATOR; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; TACHYCARDIA;

AGED; BIOLOGICAL MARKERS; DEFIBRILLATORS, IMPLANTABLE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33847346765     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.07.004     Document Type: Article

References (32)

1. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 (2004) 754-763
2. Moss A.J. Dead is dead, but can we identify patients at increased risk for sudden cardiac death?. J Am Coll Cardiol 42 (2003) 659-660
3. Franz M.R. Mechano-electrical feedback in ventricular myocardium. Cardiovasc Res 32 (1996) 15-24
4. Zhu W.X., Johnson S.B., Brandt R., Burnett J., and Packer D.L. Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. J Am Coll Cardiol 30 (1997) 825-833
5. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
6. Doust J.A., Pietrzak E., Dobson A., and Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330 (2005) 625
7. Christ M., Grimm W., Rostig S., et al. Association of right ventricular dysfunction and Cheyne-Stokes respiration in patients with chronic heart failure. J Sleep Res 12 (2003) 161-167
8. Wu A.H., Packer M., Smith A., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50 (2004) 867-873
9. Grimm W., Hoffmann J.J., Muller H.H., and Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 39 (2002) 780-787
10. Marchlinski F.E., Gottlieb C.D., Sarter B., et al. ICD data storage: value in arrhythmia management. Pacing Clin Electrophysiol 16 (1993) 527-534
11. Hook B.G., and Marchlinski F.E. Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy. J Am Coll Cardiol 17 (1991) 985-990
12. Bocker D., Block M., Isbruch F., et al. Do patients with an implantable defibrillator live longer?. J Am Coll Cardiol 21 (1993) 1638-1644
13. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
14. Christ M., Klima T., Grimm W., Mueller H.H., and Maisch B. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 27 (2006) 691-699
15. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283 (2000) 1295-1302
16. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
17. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 (2002) 131-138
18. Hesse B., Diaz L.A., Snader C.E., Blackstone E.H., and Lauer M.S. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med 110 (2001) 253-259
19. Fahy G.J., Pinski S.L., Miller D.P., et al. Natural history of isolated bundle branch block. Am J Cardiol 77 (1996) 1185-1190
20. Baldasseroni S., Opasich C., Gorini M., et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 143 (2002) 398-405
21. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
22. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
23. Pratt C.M., Greenway P.S., Schoenfeld M.H., Hibben M.L., and Reiffel J.A. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 93 (1996) 519-524
24. Tapanainen J.M., Lindgren K.S., Makikallio T.H., et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 43 (2004) 757-763
25. Manios E.G., Kallergis E.M., Kanoupakis E.M., et al. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 128 (2005) 2604-2610
26. Verma A., Kilicaslan F., Martin D.O., et al. Pre-implantation B-type natriuretic peptide level is an independent predictor of future appropriate implantable defibrillator therapies. Heart 92 (2006) 190-195
27. Ellenbogen K.A., Levine J.H., Berger R.D., et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 113 (2006) 776-782
28. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
29. Hartikainen J.E., Malik M., Staunton A., Poloniecki J., and Camm A.J. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 28 (1996) 296-304
30. Buxton A.E., Lee K.L., Hafley G.E., et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 106 (2002) 2466-2472
31. Pascale P., Taffe P., Regamey C., Kappenberger L., and Fromer M. Reduced ejection fraction after myocardial infarction: is it sufficient to justify implantation of a defibrillator?. Chest 128 (2005) 2626-2632
32. Bigger Jr. J.T., Whang W., Rottman J.N., et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 99 (1999) 1416-1421